You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSaprisartan
Accession NumberDB01347
TypeSmall Molecule
GroupsApproved
DescriptionSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism.(10579749)
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Saprisartan potassium
146613-90-3
Thumb
  • InChI Key: IASZJGRIPLTJMA-UHFFFAOYSA-N
  • Monoisotopic Mass: 648.005605
  • Average Mass: 649.52
DBSALT001863
Categories
UNIIHS64NG1G69
CAS number146623-69-0
WeightAverage: 611.431
Monoisotopic: 610.049723164
Chemical FormulaC25H22BrF3N4O4S
InChI KeyInChIKey=DUEWVPTZCSAMNB-UHFFFAOYSA-N
InChI
InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
IUPAC Name
1-{[3-bromo-2-(2-trifluoromethanesulfonamidophenyl)-1-benzofuran-5-yl]methyl}-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide
SMILES
CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2-arylbenzofuran flavonoids. These are phenylpropanoids containing the 2-phenylbenzofuran moiety.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
Class2-arylbenzofuran flavonoids
Sub ClassNot Available
Direct Parent2-arylbenzofuran flavonoids
Alternative Parents
Substituents
  • 2-arylbenzofuran flavonoid
  • Phenylbenzofuran
  • 2-phenylbenzofuran
  • Sulfanilide
  • Benzofuran
  • 1,2,4,5-tetrasubstituted imidazole
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Imidazole
  • Furan
  • Cyclic alcohol
  • Azole
  • Trihalomethane
  • Primary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Halomethane
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationSaprisartan is used in the treatment of hypertension and heart failure.
PharmacodynamicsBy inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.
Mechanism of actionSaprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.647
Caco-2 permeable-0.6148
P-glycoprotein substrateSubstrate0.5611
P-glycoprotein inhibitor INon-inhibitor0.6454
P-glycoprotein inhibitor IINon-inhibitor0.5279
Renal organic cation transporterNon-inhibitor0.8625
CYP450 2C9 substrateNon-substrate0.653
CYP450 2D6 substrateNon-substrate0.7866
CYP450 3A4 substrateSubstrate0.5105
CYP450 1A2 substrateNon-inhibitor0.6561
CYP450 2C9 inhibitorInhibitor0.6267
CYP450 2D6 inhibitorNon-inhibitor0.7996
CYP450 2C19 inhibitorInhibitor0.5274
CYP450 3A4 inhibitorNon-inhibitor0.5167
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8837
Ames testNon AMES toxic0.5853
CarcinogenicityNon-carcinogens0.6378
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5781 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9673
hERG inhibition (predictor II)Inhibitor0.6568
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0151 mg/mLALOGPS
logP5.89ALOGPS
logP3.35ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)2.27ChemAxon
pKa (Strongest Basic)5.18ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.22 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity137.15 m3·mol-1ChemAxon
Polarizability54.2 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Saprisartan.
AcebutololAcebutolol may increase the hypotensive activities of Saprisartan.
AceclofenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Aceclofenac.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Saprisartan.
AliskirenSaprisartan may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Saprisartan.
AmbrisentanSaprisartan may increase the hypotensive activities of Ambrisentan.
AmifostineSaprisartan may increase the hypotensive activities of Amifostine.
AmilorideSaprisartan may increase the hyperkalemic activities of Amiloride.
AmlodipineAmlodipine may increase the hypotensive activities of Saprisartan.
AntipyrineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Antipyrine.
ApremilastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Apremilast.
ArdeparinArdeparin may increase the hyperkalemic activities of Saprisartan.
AtenololAtenolol may increase the hypotensive activities of Saprisartan.
AzapropazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azelastine.
BalsalazideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Balsalazide.
BemiparinBemiparin may increase the hyperkalemic activities of Saprisartan.
BenazeprilBenazepril may increase the hypotensive activities of Saprisartan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Saprisartan.
BenmoxinBenmoxin may increase the hypotensive activities of Saprisartan.
BenoxaprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benoxaprofen.
BepridilBepridil may increase the hypotensive activities of Saprisartan.
BetaxololBetaxolol may increase the hypotensive activities of Saprisartan.
BethanidineBethanidine may increase the hypotensive activities of Saprisartan.
BimatoprostBimatoprost may increase the hypotensive activities of Saprisartan.
BisoprololBisoprolol may increase the hypotensive activities of Saprisartan.
BosentanBosentan may increase the hypotensive activities of Saprisartan.
BretyliumBretylium may increase the hypotensive activities of Saprisartan.
BrimonidineSaprisartan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Saprisartan.
BromfenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bromfenac.
BupranololSaprisartan may increase the hypotensive activities of Bupranolol.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Saprisartan.
CandesartanCandesartan may increase the hypotensive activities of Saprisartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Saprisartan.
CaptoprilCaptopril may increase the hypotensive activities of Saprisartan.
CaroxazoneCaroxazone may increase the hypotensive activities of Saprisartan.
CarprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Saprisartan.
CarvedilolCarvedilol may increase the hypotensive activities of Saprisartan.
CastanospermineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Celecoxib.
CeliprololSaprisartan may increase the hypotensive activities of Celiprolol.
CertoparinCertoparin may increase the hyperkalemic activities of Saprisartan.
ChloroquineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Saprisartan.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Saprisartan.
CilazaprilCilazapril may increase the hypotensive activities of Saprisartan.
CiprofloxacinSaprisartan may increase the arrhythmogenic activities of Ciprofloxacin.
ClonidineClonidine may increase the hypotensive activities of Saprisartan.
ClonixinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Clonixin.
CryptenamineCryptenamine may increase the hypotensive activities of Saprisartan.
CyclosporineSaprisartan may increase the hyperkalemic activities of Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Saprisartan.
D-LimoneneThe risk or severity of adverse effects can be increased when Saprisartan is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Saprisartan.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Saprisartan.
DebrisoquinSaprisartan may increase the hypotensive activities of Debrisoquin.
DeserpidineSaprisartan may increase the hypotensive activities of Deserpidine.
DiazoxideDiazoxide may increase the hypotensive activities of Saprisartan.
DiclofenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diclofenac.
DiflunisalThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diflunisal.
DiltiazemDiltiazem may increase the hypotensive activities of Saprisartan.
DorzolamideDorzolamide may increase the hypotensive activities of Saprisartan.
DoxazosinDoxazosin may increase the hypotensive activities of Saprisartan.
DrospirenoneSaprisartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Droxicam.
EfonidipineSaprisartan may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Saprisartan.
EnalaprilatSaprisartan may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Saprisartan.
EpirizoleThe risk or severity of adverse effects can be increased when Saprisartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Saprisartan.
EpoprostenolEpoprostenol may increase the hypotensive activities of Saprisartan.
EprosartanEprosartan may increase the hypotensive activities of Saprisartan.
EtanerceptThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Saprisartan is combined with exisulind.
FelodipineFelodipine may increase the hypotensive activities of Saprisartan.
FenbufenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Saprisartan.
FenoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Flurbiprofen.
FosinoprilFosinopril may increase the hypotensive activities of Saprisartan.
FurazolidoneFurazolidone may increase the hypotensive activities of Saprisartan.
GuanabenzGuanabenz may increase the hypotensive activities of Saprisartan.
GuanadrelGuanadrel may increase the hypotensive activities of Saprisartan.
GuanethidineGuanethidine may increase the hypotensive activities of Saprisartan.
GuanfacineGuanfacine may increase the hypotensive activities of Saprisartan.
HeparinHeparin may increase the hyperkalemic activities of Saprisartan.
HexamethoniumSaprisartan may increase the hypotensive activities of Hexamethonium.
HMPL-004The risk or severity of adverse effects can be increased when Saprisartan is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Saprisartan.
HydralazineHydralazine may increase the hypotensive activities of Saprisartan.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Saprisartan.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Saprisartan.
IbuprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Saprisartan is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Saprisartan.
IndapamideIndapamide may increase the hypotensive activities of Saprisartan.
IndenololSaprisartan may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indoprofen.
IndoraminSaprisartan may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Saprisartan.
IproniazidIproniazid may increase the hypotensive activities of Saprisartan.
IrbesartanIrbesartan may increase the hypotensive activities of Saprisartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Saprisartan.
IsoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Saprisartan.
KebuzoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Saprisartan.
LacidipineSaprisartan may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Saprisartan.
LeflunomideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Saprisartan.
LisinoprilLisinopril may increase the hypotensive activities of Saprisartan.
LithiumThe serum concentration of Lithium can be increased when it is combined with Saprisartan.
LofexidineSaprisartan may increase the hypotensive activities of Lofexidine.
LornoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Saprisartan.
LoxoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lumiracoxib.
MacitentanSaprisartan may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Magnesium salicylate.
ManidipineSaprisartan may increase the hypotensive activities of Manidipine.
MasoprocolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Saprisartan.
MecamylamineMecamylamine may increase the hypotensive activities of Saprisartan.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Saprisartan is combined with Metamizole.
MethyldopaMethyldopa may increase the hypotensive activities of Saprisartan.
Methylene blueMethylene blue may increase the hypotensive activities of Saprisartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Saprisartan.
MetipranololMetipranolol may increase the hypotensive activities of Saprisartan.
MetolazoneMetolazone may increase the hypotensive activities of Saprisartan.
MetoprololMetoprolol may increase the hypotensive activities of Saprisartan.
MibefradilSaprisartan may increase the hypotensive activities of Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Saprisartan.
MinoxidilMinoxidil may increase the hypotensive activities of Saprisartan.
MoclobemideMoclobemide may increase the hypotensive activities of Saprisartan.
MoexiprilMoexipril may increase the hypotensive activities of Saprisartan.
MolsidomineMolsidomine may increase the hypotensive activities of Saprisartan.
MoxonidineSaprisartan may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nabumetone.
NadololNadolol may increase the hypotensive activities of Saprisartan.
NadroparinNadroparin may increase the hyperkalemic activities of Saprisartan.
NaftifineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Saprisartan is combined with NCX 4016.
NebivololSaprisartan may increase the hypotensive activities of Nebivolol.
NepafenacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Saprisartan.
NicardipineNicardipine may increase the hypotensive activities of Saprisartan.
NicorandilSaprisartan may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Niflumic Acid.
NiguldipineSaprisartan may increase the hypotensive activities of Niguldipine.
NilvadipineSaprisartan may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Saprisartan.
NisoldipineNisoldipine may increase the hypotensive activities of Saprisartan.
NitrendipineNitrendipine may increase the hypotensive activities of Saprisartan.
NitroprussideNitroprusside may increase the hypotensive activities of Saprisartan.
ObinutuzumabSaprisartan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Saprisartan.
OlmesartanOlmesartan may increase the hypotensive activities of Saprisartan.
OlopatadineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Saprisartan.
OrgoteinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxaprozin.
OxprenololSaprisartan may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxyphenbutazone.
ParecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Parecoxib.
PargylineSaprisartan may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Saprisartan.
PenbutololSaprisartan may increase the hypotensive activities of Penbutolol.
PentoliniumPentolinium may increase the hypotensive activities of Saprisartan.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Saprisartan.
PerindoprilPerindopril may increase the hypotensive activities of Saprisartan.
PhenelzinePhenelzine may increase the hypotensive activities of Saprisartan.
PheniprazinePheniprazine may increase the hypotensive activities of Saprisartan.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Saprisartan.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Saprisartan.
PhentolaminePhentolamine may increase the hypotensive activities of Saprisartan.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pimecrolimus.
PinacidilSaprisartan may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Saprisartan.
PirfenidoneThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Saprisartan.
PiroxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Saprisartan.
PolythiazidePolythiazide may increase the hypotensive activities of Saprisartan.
PrazosinPrazosin may increase the hypotensive activities of Saprisartan.
PropacetamolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Saprisartan.
PTC299The risk or severity of adverse effects can be increased when Saprisartan is combined with PTC299.
QuinaprilQuinapril may increase the hypotensive activities of Saprisartan.
QuinineQuinine may increase the hypotensive activities of Saprisartan.
RamiprilRamipril may increase the hypotensive activities of Saprisartan.
RasagilineRasagiline may increase the hypotensive activities of Saprisartan.
RemikirenRemikiren may increase the hypotensive activities of Saprisartan.
RescinnamineSaprisartan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Saprisartan.
ResveratrolThe risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Saprisartan.
RiociguatSaprisartan may increase the hypotensive activities of Riociguat.
RituximabSaprisartan may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rofecoxib.
SafrazineSafrazine may increase the hypotensive activities of Saprisartan.
SalicylamideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salsalate.
SelegilineSelegiline may increase the hypotensive activities of Saprisartan.
SelexipagSaprisartan may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Seratrodast.
SildenafilSildenafil may increase the antihypertensive activities of Saprisartan.
SitaxentanSaprisartan may increase the hypotensive activities of Sitaxentan.
SpiraprilSaprisartan may increase the hypotensive activities of Spirapril.
SpironolactoneSaprisartan may increase the hyperkalemic activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Saprisartan is combined with SRT501.
SulfasalazineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Saprisartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Saprisartan.
TelmisartanTelmisartan may increase the hypotensive activities of Saprisartan.
TemocaprilSaprisartan may increase the hypotensive activities of Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Saprisartan is combined with Teriflunomide.
TerlipressinSaprisartan may increase the hypotensive activities of Terlipressin.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tiaprofenic acid.
TiboloneSaprisartan may increase the hypotensive activities of Tibolone.
TicrynafenSaprisartan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Saprisartan.
TinzaparinTinzaparin may increase the hyperkalemic activities of Saprisartan.
TolazolineTolazoline may increase the hypotensive activities of Saprisartan.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Saprisartan.
TolvaptanTolvaptan may increase the hyperkalemic activities of Saprisartan.
TorasemideTorasemide may increase the hypotensive activities of Saprisartan.
TrandolaprilTrandolapril may increase the hypotensive activities of Saprisartan.
TranilastThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Saprisartan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Saprisartan.
TravoprostTravoprost may increase the hypotensive activities of Saprisartan.
TreprostinilTreprostinil may increase the hypotensive activities of Saprisartan.
TriamtereneSaprisartan may increase the hyperkalemic activities of Triamterene.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Saprisartan.
TrimazosinSaprisartan may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Saprisartan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Saprisartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Saprisartan.
UnoprostoneSaprisartan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Saprisartan is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Saprisartan.
VardenafilVardenafil may increase the antihypertensive activities of Saprisartan.
XylometazolineSaprisartan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Saprisartan.
ZaltoprofenThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [PubMed:10579749 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:15 / Updated on August 17, 2016 12:23